Newland Pharmaceutical Co., Ltd. (301277.SZ) has released its third quarter report for 2025. The company reported a revenue of 481 million yuan for the first three quarters, a decrease of 10.42% year-on-year. The net profit attributable to shareholders was 91.9007 million yuan, down 35.19% compared to the same period last year. The net profit attributable to shareholders after deducting non-recurring gains and losses was 83.6323 million yuan, reflecting a year-on-year decrease of 36.65%. The basic earnings per share stood at 0.2344 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments